Idefirix® becomes the first and only product recommended by SMC for the desensitization of highly sensitized patients waiting for a kidney transplant1 SMC.
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients -
/PRNewswire/ The board of directors for Hansa Biopharma AB (publ) has today resolved to issue 850,769 new class C shares and to immediately thereafter.
/PRNewswire/ The board of directors for Hansa Biopharma AB (publ) has today resolved to issue 850,769 new class C shares and to immediately thereafter.
/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and its partner Medison.